Australia markets open in 4 hours 27 minutes

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3744-0.0120 (-3.11%)
As of 03:32PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3864
Open0.3800
Bid0.3720 x 2900
Ask0.3732 x 800
Day's range0.3500 - 0.3900
52-week range0.3500 - 31.2400
Volume5,039,598
Avg. volume13,549,685
Market cap19.477M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.8000
Earnings date16 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.25
  • GlobeNewswire

    Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

    JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical ne

  • GlobeNewswire

    Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

    First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., May 16, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women,

  • GlobeNewswire

    Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

    NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The d